GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07 Submission of Matters to a Vote of Security
Holders

At theannual meetingof stockholders of Gemphire Therapeutics Inc.
(the Company) on May23, 2017, stockholders elected two ClassI
directors to the Companys Board of Directors (the Board), each to
serve three-year terms until the 2020 annual meeting of
stockholders, and ratified the appointment of Ernst YoungLLP as
the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017.

For Proposal 1, the two nominees receiving the most votes cast
were elected as directors. Proposal 2 required the affirmative
vote of the holders of a majority of shares entitled to vote and
present at the meeting.The Proposals are described in detail in
the Companysdefinitive proxystatement filed on April6, 2017 with
the Securities and Exchange Commission.

The results of the voting are shown below.

Proposal 1Election of Directors

Proposal 2Ratification of Appointment of Independent
Registered Public Accounting Firm

About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Recent Trading Information

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) closed its last trading session down -0.03 at 10.00 with 34,455 shares trading hands.